CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Authors
Yan Y.1 , Adjei A.A. 1, 3 , Mansfield A.S.1 , Markovic S.N.1 , Dronca R.S.1 , Cao S.2 , Liu X.2 , Harrington S.M.2 , Bindeman W.E.2 , Dong H.2, 7 , Jang J.S.4 , Jen J.4 , Li Y.5 , Chanana P.5 , Park S.S.6
Journal
Number of issue
8
Language
English
Status
Published
Volume
3
Year
2018
Organizations
  • 1 Division of Medical Oncology
  • 2 Mayo Clinic Cancer Center Early Therapeutic Program
  • 3 Department of Urology
  • 4 Department of Immunology|Mayo Clinic
  • 5 Mayo Clinic Center of Individualized Medicine
  • 6 Department of Biomedical Statistics and Informatics
  • 7 Department of Radiation Oncology
Share

Other records

Stienen S., Salah K., Tijssen J.G.P., Pinto Y.M., Kok W.E., Moons A.H., Bakx A.L., Van Pol P., Kortz R.A.M., Ferreira J.P., Marques I., Schroeder-Tanka J.M., Keijer J.T., Bayés-Genis A.
Circulation. Lippincott Williams & Wilkins. Vol. 137. 2018. P. 1671-1683
Kaprin A.D., Rozhkova N.I., Mazo M.L., Rozhkova N.I., Zikiryakhodzhaev A.D., Burdina I.I., Ermoshchenkova M.V., Zapirova S.B., Mazo M.L., Prokopenko S.P., Semikopenko V.A., Sukhotko A.S., Yakobs O.E.
Общество с ограниченной ответственностью Издательская группа ГЭОТАР-Медиа. 2018.